The Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has disclosed its position regarding Avadel Pharmaceuticals PLC under the Irish Takeover Panel rules. As of January 20, 2026, Vanguard holds 5,859,870 ordinary shares of Avadel, representing 6.02% of the company's securities. The disclosure follows the Irish Takeover Panel Act, 1997, which mandates transparency for holdings reaching or exceeding the 1% threshold.

No dealings in derivatives or options related to Avadel's securities were reported by Vanguard, and no indemnities or relevant agreements have been established. The company also noted that no supplemental form 8 is necessary. This transparency ensures compliance with the regulatory framework governing corporate takeovers and significant shareholdings.